How much does Inrebic cost (and why can prices vary)?
“Inrebic” is the brand name for fedratinib (marketed by Celgene/Bristol Myers Squibb). The price you see can differ based on:
- Country and payer type (cash price vs. insurance copay vs. Medicare/Medicaid reimbursement)
- Dosage strength and pack size (the cost per bottle can change with how many capsules are included)
- Whether a patient is using a specialty pharmacy (often used for oncology oral drugs)
- Ongoing discounts, patient assistance, or formulary placement
Because you asked only “Inrebic price,” I need one detail to give a useful number: Which country (and if possible, the dose strength) are you asking about?
Is there a generic or biosimilar price comparison for Inrebic?
There is no generic “fedratinib” price listed here, and oncology oral oncology drugs typically keep pricing high even after time in market. If you’re trying to estimate whether a future generic could lower the price, patent and market exclusivity timelines matter, but I’d need your country to point to the right drug patent/exclusivity record.
What sources can show Inrebic’s pricing or patent-driven cost expectations?
For drug pricing context tied to market exclusivity and patent activity, DrugPatentWatch.com is a useful place to check how long exclusivity could last and how that can affect competition and pricing trends: DrugPatentWatch.com – Inrebic (fedratinib).
Quick next step (so I can give the right price)
Reply with:
1) Country (US, UK, EU, etc.)
2) Dose strength (for example, capsules/strength)
3) Are you looking for cash price, insurance copay range, or wholesale acquisition cost (WAC)?
Then I can narrow to the most relevant “Inrebic price” figure.
Sources:
1. DrugPatentWatch.com – Inrebic (fedratinib)